Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11381663 | PMC |
| http://dx.doi.org/10.18502/ijhoscr.v18i3.16112 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Invasive pulmonary mucormycosis (IPM) is a severe opportunistic mold infection whose outcome is predominantly host driven. Preclinical proof-of-concept studies and clinical case reports in salvage therapy settings suggested a benefit of immune checkpoint inhibitors (ICIs) in IPM management. However, the kinetics of infection-induced immune paralysis and optimal timing of ICI therapy remain poorly understood.
View Article and Find Full Text PDFComparison of Outcomes Between Protocolized Tacrolimus-Based and Non-Protocolized Ciclosporin-Based Triple-Combination Therapy in Interstitial Lung Disease With Anti-MDA5-Positive Dermatomyositis: A Single-Center Retrospective Cohort Study.
Int J Rheum Dis
July 2025
Department of Rheumatology, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.
Aim: We retrospectively compared the outcomes of protocolized tacrolimus-based and non-protocolized ciclosporin-based triple-combination therapies in consecutive patients with newly diagnosed interstitial lung disease (ILD) and antimelanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis (DM).
Methods: Clinical data from consecutive adult patients with newly diagnosed anti-MDA5-positive DM-associated ILD in our hospital from 2013 to 2022 were analyzed. Recent cases received protocolized therapy with high-dose glucocorticoids (GCs), tacrolimus, and intravenous cyclophosphamide (IVCY).
Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin.
N Engl J Med
July 2025
University of Queensland, Brisbane, Australia.
Background: Allogeneic peripheral-blood stem-cell transplantation (SCT) from a matched related donor after myeloablative conditioning is the preferred curative treatment for patients with high-risk blood cancers. The combination of a calcineurin inhibitor and an antimetabolite remains standard care for graft-versus-host disease (GVHD) prophylaxis in these patients. Data from two randomized trials have suggested that post-transplantation cyclophosphamide can reduce the risk of GVHD after SCT from a matched donor when it is added to or replaces the antimetabolite.
View Article and Find Full Text PDFIntroduction: Breast cancer is a major global health concern among all malignancies, with HER2-positive breast cancer representing a particularly aggressive subtype. It affects approximately 20% of patients and is associated with a high risk of relapse. The management of HER2-positive breast cancer has been significantly improved by targeted therapies, though challenges remain, especially in resource-limited settings.
View Article and Find Full Text PDFEconomic Evaluation of Rituximab Versus Corticosteroid-Cyclophosphamide or Cyclosporine in Patients With Membranous Nephropathy in Republic of Korea.
Nephrology (Carlton)
June 2025
Department of Nephrology, Ajou University School of Medicine, Suwon, Republic of Korea.
Background: Cyclic corticosteroid-cyclophosphamide or cyclosporine is a well-known membranous nephropathy (MN) treatment but has high risks of adverse drug reactions (ADRs). Rituximab has a non-inferior effect compared to previous treatments, with fewer ADRs. However, the high cost of rituximab is a pharmacoeconomic disincentive.
View Article and Find Full Text PDF